{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:31Z","timestamp":1788412471541,"version":"build-2803163510"},"reference-count":57,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon\u2010like peptide\u20101 (GLP\u20101)\u2010based therapies in T1D remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a review of published studies examining the CV, clinical, and renal effects of GLP\u20101\u2010based therapies in people with T1D, while also evaluating safety outcomes and future research priorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three observational real\u2010world studies evaluating GLP\u20101\u2010based therapies in adults with T1D were identified. Overall, these studies demonstrated clinically meaningful reductions in all\u2010cause mortality, hospitalisation, heart failure, and composite CV outcomes. Renal benefits were also observed, including lower risks of early estimated glomerular filtration rate decline and end\u2010stage kidney disease. Importantly, no consistent increase in diabetic ketoacidosis or severe hypoglycemia was identified, supporting a generally reassuring safety profile. These findings challenge the traditional view of GLP\u20101 receptor agonists as therapies of predominantly glycemic relevance in T1D and support their potential role in cardiorenal risk reduction. Nevertheless, the currently available evidence is entirely observational and warrants confirmation through prospective randomised studies specifically designed for T1D populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current real\u2010world evidence suggests that GLP\u20101\u2010based therapies in T1D may provide clinically meaningful CV and renal benefits with a reassuring safety profile; however, adequately powered randomised trials are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71045","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:01:48Z","timestamp":1782882108000},"page":"8757-8768","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<scp>GLP<\/scp>\n                    \u20101\u2010Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-472X","authenticated-orcid":false,"given":"Anastasios","family":"Tentolouris","sequence":"first","affiliation":[{"name":"First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine National and Kapodistrian University of Athens, Laiko General Hospital  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-1326","authenticated-orcid":false,"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty University of Novi Sad  Novi Sad Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1713-3064","authenticated-orcid":false,"given":"Alexandros L.","family":"Liarakos","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, University Hospitals of Derby and Burton NHS Foundation Trust Royal Derby Hospital  Derby UK"},{"name":"School of Medicine, Faculty of Medicine and Health Sciences University of Nottingham  Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9670","authenticated-orcid":false,"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[{"name":"Diabetes Centre, Second Department of Internal Medicine Democritus University of Thrace, University Hospital of Alexandroupolis  Alexandroupolis Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[{"name":"Second Propaedeutic Department of Internal Medicine, Hippokration General Hospital Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"e_1_2_14_2_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2025"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2311526"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci25\u20100028"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679\u2010026\u201000693\u20109"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366\u2010023\u201001429\u20108"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22\u20103078"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2021.0003"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v15.i5.823"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010025\u201001183\u20108"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)32261\u2010X"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31149\u20103"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2026.109271"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70394"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70140"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2026.01.003"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16\u20100691"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16\u20100690"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(15)00436\u20102"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13911"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14090"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2500173"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003463\u2010z"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25\u20102379"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/15209156251403555"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70841"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010026\u201004274\u20100"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/15209156251362497"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2025.106624"},{"key":"e_1_2_14_36_1","unstructured":"\u201cA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS\u2010T1D\u20101).\u201dAccessed June 2026.https:\/\/clinicaltrials.gov\/study\/NCT06914895#study\u2010plan."},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15377"},{"key":"e_1_2_14_38_1","unstructured":"\u201cType 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1\u2010DISCO).\u201dAccessed June 2026.https:\/\/clinicaltrials.gov\/study\/NCT05819138?tab=study."},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom15101403"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010025\u201067701\u20109"},{"key":"e_1_2_14_42_1","unstructured":"\u201cTrial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes (RT1D).\u201dAccessed June 2026.https:\/\/clinicaltrials.gov\/study\/NCT05822609#study\u2010plan."},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.310"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds19\u20100062"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70213"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/15209156261449879"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000541228"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(21)00246\u20101"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-443-13825-6.00301-0"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112924"},{"key":"e_1_2_14_51_1","unstructured":"\u201cWeekly Subcutaneous Semaglutide as Adjunct to Closed\u2010Loop Therapy in Type 1 Diabetes Care (SEMA\u2010AP).\u201dAccessed June 2026.https:\/\/clinicaltrials.gov\/study\/NCT05205928#study\u2010plan."},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(25)00165\u20102"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16606"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2025.1579961"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1256093"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa149"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574\u2010025\u201001154\u20104"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:21:56Z","timestamp":1788409316000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/dom.71045"],"URL":"https:\/\/doi.org\/10.1111\/dom.71045","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"2026-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}